Geo Capital Gestora de Recursos Ltd Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

Geo Capital Gestora de Recursos Ltd lowered its position in Novo Nordisk A/S (NYSE:NVO) by 8.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 24,440 shares of the company’s stock after selling 2,267 shares during the period. Novo Nordisk A/S accounts for approximately 2.8% of Geo Capital Gestora de Recursos Ltd’s portfolio, making the stock its 14th biggest holding. Geo Capital Gestora de Recursos Ltd’s holdings in Novo Nordisk A/S were worth $2,528,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Syon Capital LLC raised its holdings in shares of Novo Nordisk A/S by 19.9% during the 4th quarter. Syon Capital LLC now owns 27,809 shares of the company’s stock worth $2,877,000 after acquiring an additional 4,612 shares during the period. Integrated Advisors Network LLC raised its holdings in shares of Novo Nordisk A/S by 56.6% during the 4th quarter. Integrated Advisors Network LLC now owns 8,478 shares of the company’s stock worth $877,000 after acquiring an additional 3,063 shares during the period. Cim LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $23,547,000. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $310,000. Finally, American Trust raised its holdings in shares of Novo Nordisk A/S by 2.0% during the 4th quarter. American Trust now owns 6,136 shares of the company’s stock worth $635,000 after acquiring an additional 122 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.0 %

NVO traded up $0.01 on Friday, reaching $142.50. The company’s stock had a trading volume of 2,831,653 shares, compared to its average volume of 3,320,250. The stock has a 50 day moving average of $131.39 and a two-hundred day moving average of $120.48. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $639.47 billion, a price-to-earnings ratio of 49.14, a P/E/G ratio of 1.47 and a beta of 0.41. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $144.50.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. As a group, analysts forecast that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on NVO shares. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Argus boosted their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.